Imbruvica’s revenue trend
In 1Q17, AbbVie’s (ABBV) Imbruvica generated revenue of $551 million, which reflected a ~44.7% year-over-year (or YoY) revenue rise and a 7.8% quarter-over-quarter rise.
The drug’s entry as a first-line treatment for chronic lymphocytic leukemia (or CLL) has been a key revenue driver.
In 2016, Imbruvica generated revenue of ~$1.8 billion. In 1Q17, the company estimated that over 21% of new CLL patients were starting Imbruvica as their frontline CLL therapy. AbbVie has projected net revenue from Imbruvica of more than $2.4 billion in 2017. The drug’s rising sales may boost the share price of the Health Care Select Sector SPDR ETF (XLV). AbbVie makes up ~3.7% of XLV’s total portfolio holdings.
The above graph represents Imbruvica’s revenue trajectory from 1Q16 to 1Q17. To know more about Imbruvica’s sales, read AbbVie’s Imbruvica Saw Solid Demand in 1Q17.
Imbruvica (ibrutinib), a kinase inhibitor, is indicated for the treatment of mantle cell lymphoma (or MCL) patients who have received one prior therapy.
In March 2016, Imbruvica received FDA approval as a first-line therapy for patients with CLL. In its Phase 3 RESONATE-2 trial, the drug proved efficacious in treatment-naïve CLL patients compared to traditional chemotherapy. Imbruvica is a non-chemotherapy drug in the CLL space.
In June 2016, the FDA designated Imbruvica as a breakthrough therapy for chronic graft versus host disease patients who’d failed to respond to one or more prior systemic therapies. In January 2017, Imbruvica received FDA approval for relapsed/refractory marginal zone lymphoma (or MZL).
In the next article, we’ll discuss various ongoing clinical trials for Imbruvica and Venclexta in greater detail.